Insight into the kinetic of amyloid β(1-42) peptide self-aggregation:: Elucidation of inhibitors' mechanism of action

被引:324
作者
Bartolini, Manuela [1 ]
Bertucci, Carlo [1 ]
Bolognesi, Maria Laura [1 ]
Cavalli, Andrea [1 ]
Melchiorre, Carlo [1 ]
Andrisano, Vincenza [1 ]
机构
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
关键词
Alzheimer's disease; amyloid beta (1-42) peptide; circular dichroism; conformational transition; mechanism of inhibition;
D O I
10.1002/cbic.200700427
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The initial transition of amyloid beta (1-42) (A beta 42) soluble monomers/small oligomers from unordered/alpha-helix to a beta-sheet-rich conformation represents a suitable target to design new potent inhibitors and to obtain effective therapeutics for Alzheimer's disease. Under optimized conditions, this reliable and reproducible CD kinetic study showed a three-step sigmoid profile that was characterized by a log phase (prevailing unordered/alpha-helix conformation), an exponential growth phase (increasing beta-sheet secondary structure) and a plateau phase (prevailing beta-sheet secondary structure). This kinetic analysis brought insight into the inhibitors' mechanism of action. In fact, an increase in the duration of the lag phase can be related to the formation of an inhibitor-A beta complex, in which the non-amyloidogenic conformation is stabilized. When the exponential rate is affected exclusively, such as in the case of Congo red and tetracycline, then the inhibitor affinity might be higher for the pleated beta-sheet structure. Finally, by adding the inhibitor at the end of the exponential phase, the soluble protofibrils can be disrupted and the A beta amyloidogenic structure can revert into monomers/small oligomers. Congo red and tetracycline preferentially bind to amyloid in the beta-sheet conformation because both decreased the slope of the exponential growth, even if to a different extent, whereas no effect was observed for tacrine and galantamine. Some very preliminary indications can be derived about the structural requirements for binding to nonamyloidogenic or beta-sheet amyloid secondary structure for the development of potent antiaggregating agents. On these premises, memoquin, a multifunctional molecule that was designed to become a drug candidate for the treatment of Alzheimer's disease, was investigated under the reported circular dichroism assay and its anti-amyloidogenic mechanism of action was elucidated.
引用
收藏
页码:2152 / 2161
页数:10
相关论文
共 74 条
[1]   Congo red reverses amyloid beta protein-induced cellular stress in astrocytes [J].
Abe, K ;
Kato, M ;
Saito, H .
NEUROSCIENCE RESEARCH, 1997, 29 (02) :129-134
[2]  
ANDRISANO V, 1984, Patent No. 02003087035
[3]   Acetonitrile-induced conformational transitions in poly-L-lysine [J].
Arunkumar, AI ;
Kumar, TKS ;
Sivaraman, T ;
Yu, C .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 1997, 21 (04) :299-305
[4]   Globular amyloid β-peptide1-42 oligomer -: a homogenous and stable neuropathological protein in Alzheimer's disease [J].
Barghorn, S ;
Nimmrich, V ;
Striebinger, A ;
Krantz, C ;
Keller, P ;
Janson, B ;
Bahr, M ;
Schmidt, M ;
Bitner, RS ;
Harlan, J ;
Barlow, E ;
Ebert, U ;
Hillen, H .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (03) :834-847
[5]   SOLUTION CONFORMATIONS AND AGGREGATIONAL PROPERTIES OF SYNTHETIC AMYLOID BETA-PEPTIDES OF ALZHEIMERS-DISEASE - ANALYSIS OF CIRCULAR-DICHROISM SPECTRA [J].
BARROW, CJ ;
YASUDA, A ;
KENNY, PTM ;
ZAGORSKI, MG .
JOURNAL OF MOLECULAR BIOLOGY, 1992, 225 (04) :1075-1093
[6]   SOLUTION STRUCTURES OF BETA PEPTIDE AND ITS CONSTITUENT FRAGMENTS - RELATION TO AMYLOID DEPOSITION [J].
BARROW, CJ ;
ZAGORSKI, MG .
SCIENCE, 1991, 253 (5016) :179-182
[7]   β-amyloid aggregation induced by human acetylcholinesterase:: inhibition studies [J].
Bartolini, M ;
Bertucci, C ;
Cavrini, V ;
Andrisano, V .
BIOCHEMICAL PHARMACOLOGY, 2003, 65 (03) :407-416
[8]   Modulatory effects of pH, Cu+2 and sheet breakers on aggregation of amyloid peptides [J].
Beking, K ;
Hao, XL ;
Basak, S ;
Basak, A .
PROTEIN AND PEPTIDE LETTERS, 2005, 12 (02) :197-202
[9]  
Bieler S, 2004, CURR DRUG TARGETS, V5, P553
[10]  
BURDICK D, 1992, J BIOL CHEM, V267, P546